Bain Capital, a private equity firm, led a $350m Series A round in Areteia Therapeutics, a clinical-stage biopharmaceutical company, with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners. “Asthma is a common disease with a high unmet need and significant impact on the health and lives of millions of patients around the world. I am excited to partner with an expert team of drug developers to advance the first-ever oral treatment for eosinophilic asthma on behalf of these patients," Jorge Bartolome, Areteia CEO.